Aurigene Pharmaceutical Services, a step-down company of Dr Reddy’s Laboratories, will invest
330 crore in a development and production facility in the Genome Valley, with an emphasis on specialised fields including therapeutic proteins, antibodies, and viral vectors.
KT Rama Rao, the Minister for Industries and Commerce of Telangana, was informed on the facilities and expansion plans of Aurigene Pharmaceutical Services in Hyderabad by Satish Reddy, Chairman of Dr. Reddy’s Laboratories, and Akhil Ravi, Chief Executive Officer of Aurigene Pharmaceutical Services.
With the current investments, they anticipate creating approximately 200 direct job positions and another 60-70 indirect job opportunities in the next three years. Further, the company envisions a significant scaling-up of its investments in the future.
Aurigene would collaborate with the world’s leading biotech innovators to facilitate the development and introduction of innovative medicines into the market.
By leveraging their expertise and resources, Aurigene aspires to contribute to the advancement of healthcare by bringing cutting-edge treatments to patients.
